Immix Biopharma, Inc. insider trading
Every open-market purchase and sale by Immix Biopharma, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $10,043 2 trades by 2 insiders
3 months later: median +55.4% (+56.8% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Immix Biopharma, Inc.’s insiders pay?
From September 6, 2023 to December 26, 2024, 6 insiders reported 13 open-market purchases and 0 sales not made under a pre-set plan in Immix Biopharma, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Hsu Jason | Director | 6 | — | — | 0 | — | December 26, 2024 |
| Marquet Magda | Director | 2 | — | — | 0 | — | September 8, 2023 |
| Ng Carey | Director | 2 | — | — | 0 | — | August 19, 2024 |
| Adams Helen C. | Director | 1 | — | — | 0 | — | September 14, 2023 |
| Buchan Jane | Director | 1 | — | — | 0 | — | September 11, 2023 |
| Morris Gabriel S | CFO | 1 | — | — | 0 | — | May 14, 2024 |